Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
Silo Pharma received a Notice of Allowance from the Canadian Intellectual Property Office for a patent application covering its lead asset SPC-15, an intranasal treatment targeting PTSD. The company holds an exclusive license for the application as part of a broader agreement with Columbia University, which follows a recent European patent grant for the same invention.
Key figures
- Drug Name
- SPC-15
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.